
Dabigatran (Pradaxa)
Photo courtesy of
Boehringer Ingelheim
The US Food and Drug Administration (FDA) has granted full approval to idarucizumab (Praxbind®), the specific reversal agent for dabigatran etexilate mesylate (Pradaxa®). Idarucizumab received accelerated approval from the FDA in October 2015. Now, the drug has full approval for use in reversing dabigatran’s anticoagulant effects in...
[Read Article]